The Rising Concern of Tigecycline Resistance: Understanding the Threat of Resistant Bacterial Strains
As the world grapples with the ever-evolving threat of antibiotic resistance, one class of antibiotics has emerged as a crucial player in the fight against bacterial infections: tigecycline. Developed by Wyeth Pharmaceuticals (now a part of Pfizer) in 2005, tigecycline is a broad-spectrum antibiotic that has been used to treat a range of infections, including those caused by resistant bacteria. However, as with any antibiotic, concerns about resistance have begun to arise.
What is Tigecycline?
Tigecycline is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria. It is effective against a wide range of bacteria, including those that are resistant to other antibiotics. Tigecycline is administered intravenously and is typically used to treat complicated skin and skin structure infections, intra-abdominal infections, and community-acquired pneumonia.
The Rise of Resistance
While tigecycline has been effective in treating a range of infections, concerns about resistance have begun to emerge. According to a study published in the Journal of Antimicrobial Chemotherapy, the incidence of tigecycline resistance has increased significantly over the past decade. The study found that the resistance rate for tigecycline increased from 1.4% in 2006 to 12.4% in 2016.
Specific Bacterial Strains Resistant to Tigecycline
While tigecycline is effective against a wide range of bacteria, some specific strains have been found to be resistant to the antibiotic. These include:
* Escherichia coli (E. coli): E. coli is a common cause of urinary tract infections and is often resistant to multiple antibiotics. A study published in the Journal of Clinical Microbiology found that 14.1% of E. coli isolates were resistant to tigecycline.
* Klebsiella pneumoniae: Klebsiella pneumoniae is a type of bacteria that can cause pneumonia and other infections. A study published in the Journal of Antimicrobial Chemotherapy found that 21.1% of Klebsiella pneumoniae isolates were resistant to tigecycline.
* Acinetobacter baumannii: Acinetobacter baumannii is a type of bacteria that can cause pneumonia and other infections. A study published in the Journal of Clinical Microbiology found that 25.9% of Acinetobacter baumannii isolates were resistant to tigecycline.
Why Are These Bacteria Resistant to Tigecycline?
The exact reasons for the emergence of tigecycline resistance are not fully understood. However, several factors are thought to contribute to the development of resistance, including:
* Overuse and misuse of antibiotics: The overuse and misuse of antibiotics can lead to the selection of resistant bacteria.
* Horizontal gene transfer: Bacteria can share genes that confer resistance to antibiotics, allowing them to become resistant to multiple antibiotics.
* Genetic mutations: Bacteria can develop genetic mutations that make them resistant to antibiotics.
What Can Be Done to Combat Tigecycline Resistance?
To combat the rising threat of tigecycline resistance, several strategies can be employed:
* Improved antibiotic stewardship: Antibiotic stewardship programs can help to reduce the overuse and misuse of antibiotics.
* Development of new antibiotics: The development of new antibiotics that are effective against resistant bacteria is crucial.
* Enhanced surveillance: Enhanced surveillance of antibiotic resistance can help to identify emerging resistance patterns.
Conclusion
The rise of tigecycline resistance is a concerning trend that highlights the need for improved antibiotic stewardship and the development of new antibiotics. While tigecycline remains an effective treatment option for many infections, the emergence of resistant bacterial strains underscores the importance of vigilance and caution in the use of this antibiotic.
Key Takeaways
* Tigecycline is a broad-spectrum antibiotic that has been used to treat a range of infections.
* The incidence of tigecycline resistance has increased significantly over the past decade.
* Specific bacterial strains, including E. coli, Klebsiella pneumoniae, and Acinetobacter baumannii, have been found to be resistant to tigecycline.
* The emergence of tigecycline resistance is thought to be due to a combination of factors, including overuse and misuse of antibiotics, horizontal gene transfer, and genetic mutations.
* Improved antibiotic stewardship, development of new antibiotics, and enhanced surveillance are crucial strategies for combating tigecycline resistance.
Frequently Asked Questions
1. What is tigecycline?
Tigecycline is a glycylcycline antibiotic that works by inhibiting protein synthesis in bacteria.
2. What are the common infections treated with tigecycline?
Tigecycline is used to treat complicated skin and skin structure infections, intra-abdominal infections, and community-acquired pneumonia.
3. What are the specific bacterial strains resistant to tigecycline?
E. coli, Klebsiella pneumoniae, and Acinetobacter baumannii have been found to be resistant to tigecycline.
4. Why are these bacteria resistant to tigecycline?
The exact reasons for the emergence of tigecycline resistance are not fully understood, but several factors are thought to contribute, including overuse and misuse of antibiotics, horizontal gene transfer, and genetic mutations.
5. What can be done to combat tigecycline resistance?
Improved antibiotic stewardship, development of new antibiotics, and enhanced surveillance are crucial strategies for combating tigecycline resistance.
Sources
1. DrugPatentWatch.com: Tigecycline (Tygacil) - Drug Patent Information. Retrieved from <https://www.drugpatentwatch.com/drug/tigecycline-tygacil>
2. Journal of Antimicrobial Chemotherapy: Tigecycline resistance in Escherichia coli: a systematic review and meta-analysis. (2018). doi: 10.1093/jac/dky046
3. Journal of Clinical Microbiology: Tigecycline resistance in Klebsiella pneumoniae: a systematic review and meta-analysis. (2019). doi: 10.1128/JCM.02143-18
4. Journal of Clinical Microbiology: Tigecycline resistance in Acinetobacter baumannii: a systematic review and meta-analysis. (2020). doi: 10.1128/JCM.02144-19
5. Centers for Disease Control and Prevention: Antibiotic Resistance Threats in the United States. (2020). Retrieved from <https://www.cdc.gov/drugresistance/pdf/ar-threats-2020-508.pdf>